APR-05-2006 09:17 From:GSK

919 483 7977 To:USPTO

P.2

FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 7-2005)			ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES PG4979USW				
DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (If known, see 37 CFR 1.5)				
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371				
INTE	RNAT	IONAL APPLICATION NO. INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED	
-	PCT/EP03/12035 October 24, 2003 October 28, 2002 TITLE OF INVENTION			
PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESIRATORY DISEASES				
APPLICANT(S) FOR DO/EO/US				
Alan Michael CHAPMAN, Stephen Barry GUNTRIP, Brian Edgar LOOKER, Panayiotis Alexandron PROCOPIOU				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
1.		☐ This is a FIRST submission of items concorning a submission under 35 U.S.C. 371.		
2.	\boxtimes	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.		
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.		
4.		The US has been elected (Article 31).		
5.		A copy of the International Application as filed (35 U.S.C. 371 (c)(2))		
		 is attached hereto (required only if not communicated by the International Bureau). 		
		b. has been communicated by the International Bureau.		
		 c. is not required, as the application was filed in the United States Receiving Office (RO/US). 		
G.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).		
ŀ		a. 🗋 is attached hereto.		
1		b. has been previously submitted under 35 U.S.C. 154(d)(4).		
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))		
		a. are attached hereto (required only if not communicated by the International Sureau).		
İ		b. have been communicated by the International Bureau.		
		c. 🔲 have not been made; however, the time limit for making such amendm	ents has NOT expired.	
1		d. have not been made and will not be made.		
8.		An English language translation of the amendments to the claims under PCT Ar	tide 19 (35 U.S.C. 371(c)(3)).	
9.	\boxtimes	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).		
10.		An English languago translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.Ş.C. 371 (c)(5)).		
11.		A copy of the International Proliminary Examination Report (PCT/IPEA/409).		
12.		A copy of the International Search Report (PCT/ISA/210).		
items 13 to 23 bolow concern document(s) or information included:				
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.		
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
15.		A FIRST preliminary amendment.		
16.		A SECOND or SUBSEQUENT preliminary amendment.		
17.		A substitute specification.		
18.	X	A power of attorney and/or change of address letter.		
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13rer.2 and 37 CFR 1.821 - 1.825.		
20.				
21.		A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).		
22.		Express Mail Label No.		
L		· · · · · · · · · · · · · · · · · · ·		

PCTUS1/REV07

Rec'd PCT/PTO -5 APR 2006

F


APR-05-2006 09:17 From:GSK

919 483 7977

To: USPTO

P.1

FAX



GlaxoSmithKline PO Box 13398 Five Moore Drive Research Triangle Park North Carolina 27709

GlaxoSmithKline

Tel: 919 483 2100 www.gsk.com

Re:

Application of Chapman et al.

Serial No.: 10/532,869; Int'l. Appl. No.: PCT/EP03/12035

Title: Phenethanolamine derivative for the Treatment of Respiratory Diseases

Attorney Docket No. PG4979USw

Attached is:

- Transmittal Letter (3 pgs; in duplicate)
- Declaration (4 pgs);
- Power of Attorney and Change of Correspondence Address (1 pg);
- 4. Statement under 3.73(b) and Corporate Resolution (POA) (4 pgs.);
- Copy of Notification of Missing Requirements under 35 USC 371, date mailed 3/10/2006

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this <u>Response to Notification of Missing Requirements</u> is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>571-273-3201</u>) on <u>April 5, 2006</u>

Patty Wilson

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.